Understanding long-term impact of MS treatment

18 July 2012

A new study co-led by MSFHR Scholar Dr. Helen Tremlett has found that a widely prescribed drug treatment for multiple sclerosis (MS) does not significantly impact the long-term progression of the disease.

The research team examined health records of more than 2,600 MS patients in British Columbia and found similar progression to disability in those treated with beta interferons and in untreated MS patients. The findings provide patients and clinicians with valuable information about the long-term effects of beta interferons and may help shape future MS treatments.

Category:

News